Methods of using [3.2.0] heterocyclic compounds and analogs thereof

a heterocyclic compound and compound technology, applied in the field of methods of using heterocyclic compounds, can solve the problems of infectious diseases, fungi and protozoa are becoming increasingly difficult to treat and cure, and the cure of diseases is difficul

Inactive Publication Date: 2005-03-03
CELGENE INT II SARL +1
View PDF49 Cites 59 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Still further embodiments relate to methods of inhibiting the growth of a cancer cell. The methods can include, for example, contacting a cancer cell with a compound of a formula selected from Formulae I-V, and pharmaceutically acceptable salts and pro-drug esters thereof.
Other embodiments relate to methods of inhibiting proteasome activity that include the step contacting a cell with a compound of a formula selected from Formulae I-V, and pharmaceutically acceptable salts and pro-drug esters thereof.
Other embodiments relate to methods of inhibiting NF-κB acti

Problems solved by technology

Surgery and radiation therapy, however, are generally useful only for fairly defined types of cancer, and are of limited use for treating patients with disseminated disease.
Although chemotherapy can provide a therapeutic benefit, it often fails to result in cure of the disease due to the patient's cancer cells becoming resistant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of using [3.2.0] heterocyclic compounds and analogs thereof
  • Methods of using [3.2.0] heterocyclic compounds and analogs thereof
  • Methods of using [3.2.0] heterocyclic compounds and analogs thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Fermentation of Compound of Formulae II-16 II-20. and II-24C

Strain CNB476 was grown in a 500-ml flask containing 100 ml of vegetative medium consisting of the following per liter of deionized water: glucose, 4 g; Bacto tryptone, 3 g; Bacto casitone, 5 g; and synthetic sea salt (Instant Ocean, Aquarium Systems), 30 g. The first seed culture was incubated at 28 degree C. for 3 days on a rotary shaker operating at 250 rpm. Four ml each of the first seed culture was inoculated into three 500-ml flasks containing of 100 ml of the vegetative medium. The second seed cultures were incubated at 28 degree C. and 250 rpm on a rotary shaker for 2 days. Four ml each of the second seed culture was inoculated into thirty-five 500-ml flasks containing of 100 ml of the vegetative medium. The third seed cultures were incubated at 28 degree and 250 rpm on a rotary shaker for 2 days. Four ml each of the third seed culture was inoculated into four hundred 500-ml flasks containing 100 ml of the product...

example 2

Purification of Compound of Formulae II-16, II-20 and II-24C

The pure compounds of Formulae II-16, II-20 and II-24C were obtained by flash chromatography followed by HPLC. Eight grams crude extract containing 3.8 grams of the compound of Formula II-16 and lesser quantities of II-20 and II-24C was processed by flash chromatography using Biotage Flash40i system and Flash 40M cartridge (KP-Sil Silica, 32-63 μm, 90 grams). The flash chromatography was developed by the following step gradient: 1. Hexane (1 L) 2. 10% Ethyl acetate in hexane (1 L) 3. 20% Ethyl acetate in hexane, first elution (1 L) 4. 20% Ethyl acetate in hexane, second elution (1 L) 5. 20% Ethyl acetate in hexane, third elution (1 L) 6. 25% Ethyl acetate in hexane (1 L) 7. 50% Ethyl acetate in hexane (1 L) 8. Ethyl acetate (1 L)

Fractions containing the compound of Formula II-16 in greater or equal to 70% UV purity by HPLC were pooled and subject to HPLC purification, as described below, to obtain II-16, along w...

example 3

Fermentation of Compounds of Formulae II-17 and II-18

Strain CNB476 was grown in a 500-ml flask containing 100 ml of the first vegetative medium consisting of the following per liter of deionized water: glucose, 4 g; Bacto tryptone, 3 g; Bacto casitone, 5 g; and synthetic sea salt (Instant Ocean, Aquarium Systems), 30 g. The first seed culture was incubated at 28 degree C. for 3 days on a rotary shaker operating at 250 rpm. Five ml of the first seed culture was inoculated into a 500-ml flask containing 100 ml of the second vegetative medium consisting of the following per liter of deionized water: starch, 10 g; yeast extract, 4 g; peptone, 2 g; ferric sulfate, 40 mg; potassium bromide, 100 mg; calcium carbonate, 1 g; and sodium bromide, 30 g. The second seed cultures were incubated at 28° C. for 7 days on a rotary shaker operating at 250 rpm. Approximately 2 to 3 gram of sterile Amberlite XAD-7 resin were added to the second seed culture. The second seed culture was further incubat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Electrical resistanceaaaaaaaaaa
Login to view more

Abstract

Disclosed are methods of treating cancer, inflammatory conditions, and/or infectious disease in an animal comprising: administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to certain compounds and to methods for the preparation and the use of certain compounds in the fields of chemistry and medicine. Embodiments of the invention disclosed herein relate to methods of using heterocyclic compounds. In some embodiments, the compounds are used as proteasome inhibitors. In other embodiments, the compounds are used to treat inflammation, cancer, and infectious diseases. 2. Description of the Related Art Cancer is a leading cause of death in the United States. Despite significant efforts to find new approaches for treating cancer, the primary treatment options remain surgery, chemotherapy and radiation therapy, either alone or in combination. Surgery and radiation therapy, however, are generally useful only for fairly defined types of cancer, and are of limited use for treating patients with disseminated disease. Chemotherapy is the method that is generally useful in treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/407A61P9/10A61P11/06A61P17/06A61P19/02A61P25/00A61P29/00A61P33/00A61P33/02A61P33/06A61P35/00A61P35/02
CPCA61K31/407A61P11/06A61P17/06A61P19/02A61P25/00A61P25/28A61P29/00A61P31/00A61P31/04A61P31/10A61P33/00A61P33/02A61P33/06A61P35/00A61P35/02A61P43/00A61P9/10Y02A50/30
Inventor PALLADINO, MICHAELNEUTEBOOM, SASKIA THEODORA CORNELIAMACHERLA, VENKATA RAMI REDDYPOTTS, BARBARA CHRISTINE
Owner CELGENE INT II SARL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap